[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
July 1955

Plimasin: A Preliminary Evaluation

Author Affiliations

Charleston, W. Va.

AMA Arch Derm. 1955;72(1):59-62. doi:10.1001/archderm.1955.03730310061012
Abstract

INTRODUCTION

Plimasin* is a new antiallergic preparation, combining 25 mg. of tripelennamine HCl (Pyribenzamine, Ciba) and 5 mg. of methyl-phenidylacetate (Ritalin, Ciba). The combination was originally used to determine whether it eliminated antihistaminic side-effects, such as drowsiness, which bother some patients. Preliminary European trials seemed to indicate that smaller doses of the antihistamine were effective when administered in Plimasin. This study is a preliminary evaluation of its effectiveness in skin conditions with special reference to its therapeutic indications.

Methyl-phenidylacetate (methyl phenyl-2piperidineacetate hydrochloride), a new synthetic compound, has a marked psychomotor stimulating effect, similar to the effect known for some phenylisopropylamines. Subcutaneous injection of 1 to 2 mg/kg. in experimental animals stimulates respiration and increases motility considerably. Its clinical effect suggests in part amphetamine, but differs from it and must be classified between it and caffeine.

STUDY

This survey covers 193 successive cases

References
1.
The material for this study was furnished by CIBA Pharmaceutical Products, Inc.
2.
Arbesman, C. E.:  Report of the Committee on New Drugs of the American Academy of Allergy , presented at the  Meeting of the American Academy of Allergy , New York, (Feb. 9) , 1955
3.
Meier, R.; Gross, F., and Tripod, J.:  Ritalin, a New Synthetic Compound with Specific Central Stimulating Component ,  Klin. Wchnschr. 32:445-450 ( (May 15) ) 1954.Crossref
4.
Arbesman, C. E.:  Clinical Studies in Allergy with Several New Drugs ,  J. Allergy 26:87-88 ( (Jan.) ) 1955.Crossref
×